Lataa...
Product review: avelumab, an anti-PD-L1 antibody
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppress...
Tallennettuna:
| Julkaisussa: | Hum Vaccin Immunother |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605872/ https://ncbi.nlm.nih.gov/pubmed/30481100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1551671 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|